In Committee
A bill to amend title XI of the Social Security Act to alter when biosimilar biological products are eligible for price negotiations under the Medicare program.
Sponsor
Sen. Blackburn, Marsha [R-TN]Republican · TennesseeCommittee
Finance CommitteeLast action
Read twice and referred to the Committee on Finance.
Sep 28, 2026
Read twice and referred to the Committee on Finance. · Sep 28, 2026
Introduced Sep 28, 2026
Members signed on after the sponsor
Offered against this measure
No roll calls stored
7 organizations reported lobbying on this bill, through 2 lobbying firms.
From Lobbying Disclosure Act reports that name this bill. Reports do not say how much of a quarter's spending went to any one bill, so none is attributed here.